Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sipeimine in preparation of medicines for preventing and/or treating ulcerative colitis

A technology for ulcerative colitis and sibesin, which is applied in the field of medicine, can solve the problems of anti-ulcerative colitis and other problems that have not been seen in sibesin, and achieves prevention and intestinal tissue pathological damage, excellent anti-ulcerative colitis activity, The effect of improving the pathological injury of intestinal tissue

Inactive Publication Date: 2021-08-06
CHANGCHUN UNIV OF CHINESE MEDICINE +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Sibeisu has the structure shown in formula I. Sibeisu is an alkaloid in the genus Fritillaria. Studies have shown that the alkaloids of the genus Fritillaria have the functions of relieving cough and expectorant, relieving asthma, lowering blood pressure, analgesia, anticancer, antibacterial, etc. Various effects, up to now, there is no related report about the anti-ulcerative colitis of sibesil

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sipeimine in preparation of medicines for preventing and/or treating ulcerative colitis
  • Application of sipeimine in preparation of medicines for preventing and/or treating ulcerative colitis
  • Application of sipeimine in preparation of medicines for preventing and/or treating ulcerative colitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Embodiment 1 sibecillin is to safety experiment

[0049] Eighteen healthy male C57BL / 6J mice with a body weight of about 20 g were randomly divided into 3 groups, 6 in each group, namely the control group, the Sibesil (9mg / kg) group and the Sibesil (18mg / kg) group. After adapting to the environment for one week, prepare sibesil with physiological saline, and administer according to the body weight of experimental mice every day, sibesil (9mg / kg) group is given sibesil for gavage administration 9mg / kg, sibesil ( 18mg / kg) group was given 18mg / kg of Sibesu by intragastric administration, and 100 μ L of normal saline was administered by intragastric administration to the control group for 7 days, and the death, body weight, intestinal tissue, colon and cecum pathological changes of each group of experimental mice were recorded simultaneously. Condition.

[0050] Experimental results such asfigure 1 , figure 2 , image 3 with Figure 4 shown. The results showed that th...

Embodiment 2

[0051] The influence of embodiment 2 sibesil on disease symptom of ulcerative colitis mice

[0052] 50 healthy male C57BL / 6J mice with a body weight of about 20 g were randomly divided into 5 groups, 10 in each group, i.e. the control group, model group, positive drug group, Sibesil (9mg / kg) group and Sibesil ( 18mg / kg) group. After adapting to the environment for one week, the mice were administered daily according to the body weight of the experimental mice. The control group drank normal water and administrated 100 μL of normal saline. Sibesu (18mg / kg) group was administered 18mg / kg by intragastric administration of Sibeisu, 100 μ L of normal saline was administered by intragastric administration to the model group, and 150 mg / kg of 5-aminosalicylic acid was administered by intragastric administration to the positive drug group. medicine for 7 days. After administration on the first day, 3% dextran sodium sulfate (Dextran Sulfate Sodium Salt, DSS) was added to the drinkin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of sipeimine in preparation of medicines for preventing and / or treating ulcerative colitis, and relates to the field of medicines. According to the invention, experiments prove that the sipeimine does not cause significant influence on experimental mice: there is no death, no significant change in body weight, no obvious lesion in intestinal tissues and no obvious pathological symptoms in colon and cecum for the experimental mice in a sipeimine group, showing that the sipeimine has certain safety. The sipeimine can reduce the weight loss rate of mice with ulcerative colitis, improve the fecal character and the hemafecia condition of the mice with ulcerative colitis, improve DAI of the mice with ulcerative colitis and effectively prevent and improve pathological damage of intestinal tissues of the mice with ulcerative colitis, suggesting that the sipeimine has particularly excellent anti-ulcerative colitis activity and certain safety, and can obviously improve ulcerative colitis symptoms.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of Sibesil in the preparation of medicines for preventing and / or treating ulcerative colitis. Background technique [0002] Ulcerative colitis is a chronic nonspecific intestinal inflammatory disease whose etiology is not yet clear, characterized by continuous and diffuse inflammatory changes in the colorectal mucosa, and its lesions are mainly limited to the large intestinal mucosa and submucosa. The clinical manifestations are diarrhea, mucus pus and blood in the stool, and abdominal pain, and it is mostly a chronic course of repeated attacks. [0003] At present, the clinical treatment of ulcerative colitis is based on the course of the disease, and aminosalicylic acid preparations (5-aminosalicylic acid or sulfasalazine, etc.), corticosteroids (prednisone or hydrocortisone, etc.) or Immunosuppressant (azathioprine or 6-mercaptopurine, etc.) to be treated. H...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61K36/8966A61P1/04A61K125/00
CPCA61K31/4375A61K36/8966A61P1/04
Inventor 朱羿龙房金波韩继成李一权白冰
Owner CHANGCHUN UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com